Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors

被引：394
作者：
Sabbah, Dima A. [1 ]
Hajjo, Rima [1 ]
Sweidan, Kamal [2 ]
机构：
[1] Al Zaytoonah Univ Jordan, Fac Pharm, Dept Pharm, POB 130, Amman 11733, Jordan
[2] Univ Jordan, Dept Chem, Amman 11942, Jordan
来源：
CURRENT TOPICS IN MEDICINAL CHEMISTRY | 2020年 / 20卷 / 10期
关键词：
EGFR; HER-1; ERBB-1; Tyrosine kinase; EGF; TGF-alpha; mAbs; Inhibitors; cancer; TYROSINE KINASE INHIBITORS; HUMAN CANCER-CELLS; PHASE-I SAFETY; MONOCLONAL-ANTIBODY; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; FACTOR-ALPHA; LUNG-CANCER; ANTITUMOR-ACTIVITY; LIGAND-BINDING;
D O I：
10.2174/1568026620666200303123102
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase receptors. EGFR signaling cascade is a key regulator in cell proliferation, differentiation, division, survival, and cancer development. In this review, the EGFR structure and its mutations, signaling pathway, ligand binding and EGFR dimerization, EGF/EGFR interaction, and the progress in the development of EGFR inhibitors have been explored.
引用
收藏
页码：815 / 834
页数：20
相关论文
共 190 条
  • [1] ABBASI M, 2018, FRONT CELL NEUROSCI, V12, DOI DOI 10.3389/FNCE1.2018.00085
  • [2] Disulfide bond structure of human epidermal growth factor receptor
    Abe, Y
    Odaka, M
    Inagaki, F
    Lax, I
    Schlessinger, J
    Kohda, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (18) : 11150 - 11157
  • [3] EFFICACY OF ANTIBODIES TO EPIDERMAL GROWTH-FACTOR RECEPTOR AGAINST KB CARCINOMA INVITRO AND IN NUDE-MICE
    ABOUDPIRAK, E
    HURWITZ, E
    PIRAK, ME
    BELLOT, F
    SCHLESSINGER, J
    SELA, M
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (20) : 1605 - 1611
  • [4] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
    Agus, DB
    Akita, RW
    Fox, WD
    Lewis, GD
    Higgins, B
    Pisacane, PI
    Lofgren, JA
    Tindell, C
    Evans, DP
    Maiese, K
    Scher, HI
    Sliwkowski, MX
    [J]. CANCER CELL, 2002, 2 (02) : 127 - 137
  • [5] AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
  • [6] The Biomolecular Interaction Network Database and related tools 2005 update
    Alfarano, C
    Andrade, CE
    Anthony, K
    Bahroos, N
    Bajec, M
    Bantoft, K
    Betel, D
    Bobechko, B
    Boutilier, K
    Burgess, E
    Buzadzija, K
    Cavero, R
    D'Abreo, C
    Donaldson, I
    Dorairajoo, D
    Dumontier, MJ
    Dumontier, MR
    Earles, V
    Farrall, R
    Feldman, H
    Garderman, E
    Gong, Y
    Gonzaga, R
    Grytsan, V
    Gryz, E
    Gu, V
    Haldorsen, E
    Halupa, A
    Haw, R
    Hrvojic, A
    Hurrell, L
    Isserlin, R
    Jack, F
    Juma, F
    Khan, A
    Kon, T
    Konopinsky, S
    Le, V
    Lee, E
    Ling, S
    Magidin, M
    Moniakis, J
    Montojo, J
    Moore, S
    Muskat, B
    Ng, I
    Paraiso, JP
    Parker, B
    Pintilie, G
    Pirone, R
    [J]. NUCLEIC ACIDS RESEARCH, 2005, 33 : D418 - D424
  • [7] Arena C., 2018, CLIN ONCOL-UK, V3, P1549
  • [8] Architecture and Membrane Interactions of the EGF Receptor
    Arkhipov, Anton
    Shan, Yibing
    Das, Rahul
    Endres, Nicholas F.
    Eastwood, Michael P.
    Wemmer, David E.
    Kuriyan, John
    Shaw, David E.
    [J]. CELL, 2013, 152 (03) : 557 - 569
  • [9] Role of tyrosine kinase inhibitors in cancer therapy
    Arora, A
    Scholar, EM
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) : 971 - 979
  • [10] Targeting HERI/EGFR: A molecular approach to cancer therapy
    Arteaga, C
    [J]. SEMINARS IN ONCOLOGY, 2003, 30 (03) : 3 - 14
12345678910